IL285999B2 - JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction - Google Patents

JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction

Info

Publication number
IL285999B2
IL285999B2 IL285999A IL28599921A IL285999B2 IL 285999 B2 IL285999 B2 IL 285999B2 IL 285999 A IL285999 A IL 285999A IL 28599921 A IL28599921 A IL 28599921A IL 285999 B2 IL285999 B2 IL 285999B2
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
pathway inhibitor
jak1 pathway
subject
Prior art date
Application number
IL285999A
Other languages
English (en)
Hebrew (he)
Other versions
IL285999B1 (en
IL285999A (en
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of IL285999A publication Critical patent/IL285999A/en
Publication of IL285999B1 publication Critical patent/IL285999B1/en
Publication of IL285999B2 publication Critical patent/IL285999B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL285999A 2019-03-05 2020-03-05 JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction IL285999B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814085P 2019-03-05 2019-03-05
PCT/US2020/021088 WO2020181034A1 (en) 2019-03-05 2020-03-05 Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction

Publications (3)

Publication Number Publication Date
IL285999A IL285999A (en) 2021-10-31
IL285999B1 IL285999B1 (en) 2025-09-01
IL285999B2 true IL285999B2 (en) 2026-01-01

Family

ID=69941525

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285999A IL285999B2 (en) 2019-03-05 2020-03-05 JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction

Country Status (15)

Country Link
US (2) US11406640B2 (enExample)
EP (2) EP4691567A3 (enExample)
JP (2) JP2022524997A (enExample)
KR (1) KR20210137087A (enExample)
CN (1) CN114007621A (enExample)
AU (1) AU2020232757B2 (enExample)
CA (1) CA3132371A1 (enExample)
EA (1) EA202192426A1 (enExample)
IL (1) IL285999B2 (enExample)
MA (1) MA55201A (enExample)
MX (2) MX2021010545A (enExample)
PH (1) PH12021552130A1 (enExample)
SG (1) SG11202109563WA (enExample)
UA (1) UA130579C2 (enExample)
WO (1) WO2020181034A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004063A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas heterocíclicas com 5 a 7 membros como inibidores de jak
DK3837258T3 (da) 2018-09-04 2024-07-22 Theravance Biopharma R&D Ip Llc Dimethyl amino azetidine amides as jak inhibitors
EP3853229A1 (en) 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
KR20210109522A (ko) 2018-10-31 2021-09-06 인사이트 코포레이션 혈액 질환의 치료를 위한 병용 요법
UA130579C2 (uk) * 2019-03-05 2026-03-25 Інсайт Корпорейшн Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
KR20220149585A (ko) 2020-03-02 2022-11-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제 화합물의 결정성 수화물
CN117120055A (zh) * 2021-01-11 2023-11-24 因赛特公司 包含jak通路抑制剂和rock抑制剂的组合疗法
CA3207859A1 (en) * 2021-01-11 2022-07-14 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
KR102952944B1 (ko) 2021-10-15 2026-04-14 주식회사 엘지에너지솔루션 용접봉 체결 방법 및 이에 의해 용접봉이 수직으로 체결된 용접 장치

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021153A1 (en) * 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015131031A1 (en) * 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
WO2018099680A1 (en) * 2016-11-29 2018-06-07 Sandoz Ag Citrate salts of a janus kinase (jak) inhibitor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2001881A2 (en) 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2684564A1 (en) 2008-04-17 2014-01-15 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP4782062A2 (en) 2009-12-01 2026-07-29 AbbVie Inc. Novel tricyclic compounds
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
CR20190156A (es) * 2013-05-17 2019-05-16 Incyte Corp Derivados de bipirazol como inhibidores jak
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
TWI710560B (zh) 2015-11-03 2020-11-21 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療呼吸疾病之jak激酶抑制劑化合物
CN105294699B (zh) * 2015-12-04 2019-06-11 上海勋和医药科技有限公司 巴瑞替尼的制备方法
EA201990523A1 (ru) * 2016-10-03 2019-10-31 НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
TWI754019B (zh) 2017-03-09 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 含有4員雜環醯胺之jak抑制劑
AU2018261588A1 (en) 2017-05-01 2019-10-31 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
CA3091339A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
KR20260080448A (ko) 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
KR20210109522A (ko) 2018-10-31 2021-09-06 인사이트 코포레이션 혈액 질환의 치료를 위한 병용 요법
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
UA130579C2 (uk) 2019-03-05 2026-03-25 Інсайт Корпорейшн Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021153A1 (en) * 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015131031A1 (en) * 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
WO2018099680A1 (en) * 2016-11-29 2018-06-07 Sandoz Ag Citrate salts of a janus kinase (jak) inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOETTLER MICHELLE ET AL,, RUXOLITINIB IS AN EFFECTIVE STEROID SPARING AGENT IN CHILDREN WITH STEROID REFRACTORY/DEPENDENT BRONCHIOLITIS OBLITERANS SYNDROME AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION, 25 January 2019 (2019-01-25) *
GOROSPE SARASUA L ET AL,, RADIOLOGICAL IMPROVEMENT OF BRONCHIOLITIS OBLITERANS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT TREATED WITH RUXOLITINIB, 1 December 2018 (2018-12-01) *
SCHOETTLER MICHELLE ET AL,, RUXOLITINIB AND STEROID REFRACTORY/DEPENDENT BRONCHIOLITIS OBLITERANS AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STEROID SPARING AGENT THAT ALSO RESULTED IN IMPROVED LUNG FUNCTION IN CHILDREN, 29 November 2018 (2018-11-29) *

Also Published As

Publication number Publication date
MX2024007081A (es) 2024-06-21
US11406640B2 (en) 2022-08-09
EP4691567A2 (en) 2026-02-11
JP2022524997A (ja) 2022-05-11
UA130579C2 (uk) 2026-03-25
AU2020232757B2 (en) 2025-09-11
SG11202109563WA (en) 2021-09-29
PH12021552130A1 (en) 2022-08-31
WO2020181034A1 (en) 2020-09-10
US20200281931A1 (en) 2020-09-10
EP4691567A3 (en) 2026-04-29
AU2020232757A1 (en) 2021-10-07
CA3132371A1 (en) 2020-09-10
IL285999B1 (en) 2025-09-01
KR20210137087A (ko) 2021-11-17
MA55201A (fr) 2022-01-12
MX2021010545A (es) 2021-11-17
US20220331325A1 (en) 2022-10-20
IL285999A (en) 2021-10-31
US11896595B2 (en) 2024-02-13
CN114007621A (zh) 2022-02-01
EP3934651A1 (en) 2022-01-12
EA202192426A1 (ru) 2021-11-15
JP2025087734A (ja) 2025-06-10

Similar Documents

Publication Publication Date Title
US11896595B2 (en) JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US10675284B2 (en) Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
TWI835786B (zh) 使用ｊａｋ抑制劑治療化膿性汗腺炎
TW202039459A (zh) Alk5 抑制劑
WO2019224773A1 (en) Heterocyclic amides as rip1 kinase inhibitors
US20240293411A1 (en) Combination therapy comprising jak pathway inhibitor and rock inhibitor
EA044660B1 (ru) Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких
US20240058343A1 (en) Treatment of urticaria using jak inhibitors
EA050167B1 (ru) Комбинированная терапия, включающая ингибитор пути jak и ингибитор rock
EA045057B1 (ru) Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k